"Today marks a significant milestone in Lavie Bio's journey," said Amit Noam, CEO of Lavie Bio. "By combining our capabilities with ICL's expertise, we can further accelerate the development of groundbreaking ag-biological products that will provide innovative solutions to farmers around the world." This transaction follows strategic investment by ICL Planet and more than two years of close collaboration between ICL and Lavie Bio, focused on developing innovative bio-stimulant solutions for row crops facing ...

Core Insights - Lavie Bio is a leader in the ag-biologicals industry with a strong pipeline of microbiome-based products [1] - ICL will acquire key assets from Lavie Bio, including its core team, BDD technology platform, microbial bank, and commercial products [1] - The transaction follows over two years of collaboration between ICL and Lavie Bio to develop bio-stimulant solutions for crops [2] - The integration aims to accelerate the development of innovative ag-biological products for global agriculture [3] Company Overview - Lavie Bio, a subsidiary of Evogene Ltd., focuses on enhancing food quality and agricultural productivity through microbiome-based products [4] - The company utilizes a proprietary computational predictive platform, the BDD platform, powered by Evogene's MicroBoost AI technology [4] - Evogene Ltd. aims to revolutionize life-science product development using advanced technologies to improve success rates and reduce costs [6] Strategic Implications - The acquisition is expected to significantly advance the global ag-biologicals field and foster impactful agricultural innovations [3] - Existing agreements between Lavie Bio and its partners will remain with Lavie Bio, potentially generating future revenue for its shareholders [1]